Dilated Cardiomyopathy - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Dilated Cardiomyopathy - Pipeline Review, H2 2015’, provides an overview of the Dilated Cardiomyopathy’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Dilated Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dilated Cardiomyopathy and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Dilated Cardiomyopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Dilated Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dilated Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dilated Cardiomyopathy Overview 6
Therapeutics Development 7
Pipeline Products for Dilated Cardiomyopathy - Overview 7
Pipeline Products for Dilated Cardiomyopathy - Comparative Analysis 8
Dilated Cardiomyopathy - Therapeutics under Development by Companies 9
Dilated Cardiomyopathy - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Dilated Cardiomyopathy - Products under Development by Companies 13
Dilated Cardiomyopathy - Companies Involved in Therapeutics Development 14
Array BioPharma Inc. 14
Hemostemix Ltd 15
Kasiak Research Private Limited 16
Sanofi 17
Vericel Corporation 18
Dilated Cardiomyopathy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ACP-01 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ARRY-797 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CAP-1002 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Drugs for Dilated Cardiomyopathy - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ixmyelocel-T - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Refacell-DCM - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule for Dilated Cardiomyopathy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Dilated Cardiomyopathy - Recent Pipeline Updates 38
Dilated Cardiomyopathy - Dormant Projects 47
Dilated Cardiomyopathy - Product Development Milestones 48
Featured News & Press Releases 48
Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T 48
Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 48
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 48
Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 49
Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting 50
May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients 50
May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions 51
Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T 51
Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 52
Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55
List Of Tables
Number of Products under Development for Dilated Cardiomyopathy, H2 2015 7
Number of Products under Development for Dilated Cardiomyopathy - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Comparative Analysis by Unknown Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc., H2 2015 14
Dilated Cardiomyopathy - Pipeline by Hemostemix Ltd, H2 2015 15
Dilated Cardiomyopathy - Pipeline by Kasiak Research Private Limited, H2 2015 16
Dilated Cardiomyopathy - Pipeline by Sanofi, H2 2015 17
Dilated Cardiomyopathy - Pipeline by Vericel Corporation, H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 20
Number of Products by Stage and Mechanism of Action, H2 2015 21
Number of Products by Stage and Route of Administration, H2 2015 23
Number of Products by Stage and Molecule Type, H2 2015 25
Dilated Cardiomyopathy Therapeutics - Recent Pipeline Updates, H2 2015 38
Dilated Cardiomyopathy - Dormant Projects, H2 2015 47
List Of Figures
Number of Products under Development for Dilated Cardiomyopathy, H2 2015 7
Number of Products under Development for Dilated Cardiomyopathy - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 11
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Top 10 Routes of Administration, H2 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 22
Number of Products by Top 10 Molecule Types, H2 2015 24
Number of Products by Stage and Top 10 Molecule Types, H2 2015 24
